These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6120324

  • 1. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.
    Alvan G, von Bahr C, Seidemann P, Sjöqvist F.
    Lancet; 1982 Feb 06; 1(8267):333. PubMed ID: 6120324
    [No Abstract] [Full Text] [Related]

  • 2. Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.
    Rawlins MD.
    Q J Med; 1985 Feb 06; 54(214):115-6. PubMed ID: 3983355
    [No Abstract] [Full Text] [Related]

  • 3. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA, James CA, Rogers HJ.
    Eur J Clin Pharmacol; 1989 Feb 06; 36(3):319-21. PubMed ID: 2744073
    [Abstract] [Full Text] [Related]

  • 4. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J, Gasser R, Dayer P, Kronbach T, Catin T, Meyer UA.
    FEBS Lett; 1984 Aug 06; 173(2):287-90. PubMed ID: 6146537
    [Abstract] [Full Text] [Related]

  • 5. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS, Jackson PR, Freestone S, Ramsay LE, Tucker GT, Woods HF.
    Br J Clin Pharmacol; 1984 Aug 06; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract] [Full Text] [Related]

  • 6. Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.
    Toutoungi M, Magnenat D.
    Eur J Clin Pharmacol; 1990 Aug 06; 38(6):633-4. PubMed ID: 2373140
    [No Abstract] [Full Text] [Related]

  • 7. Debrisoquine hydroxylation polymorphism and personality.
    Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D.
    Lancet; 1989 Mar 11; 1(8637):555. PubMed ID: 2564084
    [No Abstract] [Full Text] [Related]

  • 8. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS, Silas JH, Freestone S, Trevethick J.
    Br J Clin Pharmacol; 1982 Aug 11; 14(2):301-3. PubMed ID: 6125207
    [Abstract] [Full Text] [Related]

  • 9. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS, Tucker GT, Woods HF.
    Clin Pharmacokinet; 1986 Aug 11; 11(1):1-17. PubMed ID: 2868819
    [Abstract] [Full Text] [Related]

  • 10. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
    McManus ME, Boobis AR, Minchin RF, Schwartz DM, Murray S, Davies DS, Thorgeirsson SS.
    Cancer Res; 1984 Dec 11; 44(12 Pt 1):5692-7. PubMed ID: 6498831
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E, Buemi AL, Sanz E, Bertilsson L.
    Ther Drug Monit; 1989 Nov 11; 11(6):721-3. PubMed ID: 2595755
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
    Küpfer A, Al-Dabbagh SG, Ritchie JC, Idle JR, Smith RL.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3193-9. PubMed ID: 7150348
    [Abstract] [Full Text] [Related]

  • 17. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
    Bertilsson L, Mellström B, Sjökvist F, Mårtenson B, Asberg M.
    Lancet; 1981 Mar 07; 1(8219):560-1. PubMed ID: 6111662
    [No Abstract] [Full Text] [Related]

  • 18. Debrisoquine hydroxylation phenotypes in healthy volunteers.
    Llerena A, Cobaleda J, Benítez J.
    Lancet; 1989 Jun 17; 1(8651):1398. PubMed ID: 2567421
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K, Gram LF, Haghfelt T, Bertilsson L.
    Pharmacol Toxicol; 1987 Apr 17; 60(4):312-4. PubMed ID: 3588528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.